SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.

SG&A Efficiency: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Viatris Inc. and Iovance Biotherapeutics, Inc. have showcased contrasting strategies in managing these costs.

Viatris Inc., a global healthcare giant, has consistently maintained high SG&A expenses, peaking at approximately $4.65 billion in 2023. This reflects a strategic investment in expansive operations and market penetration. In contrast, Iovance Biotherapeutics, a burgeoning biotech firm, has seen its SG&A expenses grow from a modest $9.3 million in 2014 to over $106 million in 2023, marking a staggering increase of over 1,000%. This growth underscores Iovance's aggressive push towards innovation and market entry.

These trends highlight the diverse approaches companies take in balancing operational costs with growth ambitions, offering valuable insights for investors and industry analysts alike.